KLHL42 and primary cutaneous T-cell non-Hodgkin lymphoma: Collectively, the aberrant expression of KLHL42 might play an important role in disease progression of CTCL, and targeting KLHL42 inhibition might serve as a promising therapeutic approach for CTCL treatment.